Serge Y. Fuchs

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

S1. Frequency of Pan-IN lesion types in KC versus KCC mice. S2. Re-expression of Ch25h in PDAC cell lines. S3. Presence of exogenous lipids diminishes effect of Ch25h re-expression in PDAC. S4. Re-expression of Ch25h does not affect Ras localization. S5. CH25H decreases autophagic flux in PDAC cells. S6. Ch25h slows PDAC tumor growth.

Year:

2025

Cholesterol dependence is an essential characteristic of pancreatic ductal adenocarcinoma (PDAC). Cholesterol 25-hydroxylase (CH25H) catalyzes monooxygenation of cholesterol into 25-hydroxycholesterol, which is implicated in inhibiting cholesterol biosynthesis and in cholesterol depletion. Here, we show that, within PDAC cells, accumulation of cholesterol was facilitated by the loss of CH25H. Methylation of the CH25H gene and decreased levels of CH25H expression occurred in human pancreatic cancers and was associated with poor prognosis. Knockout of Ch25h in mice accelerated progression of Kras -driven pancreatic intraepithelial neoplasia. Conversely, restoration of CH25H expression in human and mouse PDAC cells decreased their viability under conditions of cholesterol deficit, and decelerated tumor growth in immune competent hosts. Mechanistically, the loss of CH25H promoted autophagy resulting in downregulation of MHC-I and decreased CD8 + T-cell tumor infiltration. Re-expression of CH25H in PDAC cells combined with immune checkpoint inhibitors notably inhibited tumor growth. We discuss additional benefits that PDAC cells might gain from inactivation of CH25H and the potential translational importance of these findings for therapeutic approaches to PDAC. Implications: Loss of CH25H by pancreatic cancer cells may stimulate tumor progression and interfere with immunotherapies.

Year:

2025

Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T-cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEV) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and antitumor activity of CAR T cells but also improved endogenous antitumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T-cell therapy against solid tumors. Significance: Small extracellular vesicles secreted by solid tumors inhibit CAR T cells, which provide a molecular explanation for CAR T-cell resistance and suggests that strategies targeting exosome secretion may enhance CAR T-cell efficacy. See related commentary by Ortiz-Espinosa and Srivastava, p. 2637

Year:

2025

Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Treg cells somehow avoid fragility; however, the mechanisms by which Treg cells are protected from fragility in the tumor microenvironment are not well understood. Here, we demonstrate that the IFNAR1 chain of the type I IFN (IFN1) receptor was downregulated on intratumoral Treg cells. Downregulation of IFNAR1 mediated by p38α kinase protected Treg cells from fragility and maintained NRP1 levels, which were decreased in response to IFN1. Genetic or pharmacologic inactivation of p38α and stabilization of IFNAR1 in Treg cells induced fragility and inhibited their immune suppressive and protumorigenic activities. The inhibitor of sumoylation TAK981 (Subasumstat) upregulated IFNAR1, eliciting Treg fragility and inhibiting tumor growth in an IFNAR1-dependent manner. These findings describe a mechanism by which intratumoral Treg cells retain immunosuppressive activities and suggest therapeutic approaches for inducing Treg fragility and increasing the efficacy of immunotherapies.

Year:

2025

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEVs) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and anti-tumor activity of CAR T cells but also improved endogenous anti-tumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T cell therapy against solid tumors.

Year:

2024

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEVs) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and anti-tumor activity of CAR T cells but also improved endogenous anti-tumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T cell therapy against solid tumors.

Year:

2024

S2. AGS cells infected with either control or miR-217 were exposed to Tg (300nM) for 0, 2, 5 and 8 hours. Cells were exposed to actinomycin D (2 ᵰ7g/ml) where indicated after 5 hours of Tg treatment (and kept throughout the indicated timepoint). MiR-211 and miR-217 expression levels were quantified by qPCR. Error bars represent standard deviation for three independent experiments.

Year:

2024

S1. a) MiR-217 levels were quantified by qPCR following exposure of cells to Tg (300nM) and a small-molecule PERK inhibitor (left). PERK, ATF4 and CHOP induction were assessed by immunoblot (right). (b) eIF2S/S or eIF2A/A MEFs were treated with Tg (300nM) for indicated intervals and miR-217 levels were quantified by qPCR (right panels; n=3). (c) Co-expression analysis of miR-217 and EZH2 in different human cancers using ENCORI. (d) hsa-mir-217 cluster derived from miRbase.

Year:

2024

S2. AGS cells infected with either control or miR-217 were exposed to Tg (300nM) for 0, 2, 5 and 8 hours. Cells were exposed to actinomycin D (2 ᵰ7g/ml) where indicated after 5 hours of Tg treatment (and kept throughout the indicated timepoint). MiR-211 and miR-217 expression levels were quantified by qPCR. Error bars represent standard deviation for three independent experiments.

Year:

2024

Rapidly proliferating cancer cells require a microenvironment where essential metabolic nutrients like glucose, oxygen, and growth factors become scarce as the tumor volume surpasses the established vascular capacity of the tissue. Limits in nutrient availability typically trigger growth arrest and/or apoptosis to prevent cellular expansion. However, tumor cells frequently co-opt cellular survival pathways thereby favoring cell survival under this environmental stress. The unfolded protein response (UPR) pathway is typically engaged by tumor cells to favor adaptation to stress. PERK, an endoplasmic reticulum (ER) protein kinase and UPR effector is activated in tumor cells and contributes tumor cell adaptation by limiting protein translation and balancing redox stress. PERK also induces miRNAs that contribute to tumor adaptation. miR-211 and miR-216b were previously identified as PERK-ATF4–regulated miRNAs that regulate cell survival. We have identified another PERK-responsive miRNA, miR-217, with increased expression under prolonged ER stress. Key targets of miR-217 are identified as TRPM1 , the host gene for miR-211 and EZH2 . Evidence is provided that miR-217 expression is essential for the rapid loss of miR-211 in prolonged ER stress and provides a functional link for determining whether cells adapt to stress or commit to apoptosis. Implications: PERK-dependent induction of miR-217 limits accumulation and function of the prosurvival miRNA, miR-211, to establish cell fate and promote cell commitment to apoptosis.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (20)

Yulia Nefedova

The Wistar Institute

UNITED STATES
View details

Davide Ruggero

Professor

University of California

UNITED STATES
View details

Zebin Xiao

Professor

University of Pennsylvania

UNITED STATES
View details

Pengfei Yu

University of Pennsylvania

UNITED STATES
View details

Ben Stanger

University of Pennsylvania

UNITED STATES
View details

Jason Pitarresi

Assistant professor

University of Massachusetts Chan Medical School

UNITED STATES
View details

J. Alan Diehl

University of Pennsylvania

UNITED STATES
View details

Anil K. Rustgi

Columbia University

UNITED STATES
View details

Carl H. June

Professor

University of Pennsylvania

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

M. Andres Blanco

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Neil C. Sheppard

PI

University of Pennsylvania

UNITED STATES
View details

Meenhard Herlyn

Professor, Director

The Wistar Institute

UNITED STATES
View details

Igor Astsaturov

Professor

Fox Chase Cancer Center

UNITED STATES
View details

Hallgeir Rui

Professor

Thomas Jefferson University

UNITED STATES
View details

Jose Conejo-Garcia

Duke Science and Technology Scholar

Duke Medicine

UNITED STATES
View details

Enrico Radaelli

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Wei Guo

University of Pennsylvania

UNITED STATES
View details

Costas Koumenis

Richard H. Chamberlain Professor with Tenure

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Christina Cho

Assistant Professor

The University of Iowa

UNITED STATES
View details